Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest ondansetron Stories

2014-04-09 08:28:17

TEL AVIV, Israel, April 9, 2014 /PRNewswire/ -- Medison Pharma has concluded an agreement with the medical device company Brainsway for exclusive marketing and distribution of the Deep TMS (Transcranial Magnetic Stimulation) system in Israel. Medison Pharma will be Brainsway's exclusive agent for a period of 10 years with a 5 year extension option for the system's treatment of the following indications approved by the Israeli Ministry of Health: Major depression, Bipolar...

2014-03-06 08:30:23

-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE, March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the...

2014-03-03 08:31:55

ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults MOUNTAIN VIEW, Calif., March 3, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE(®) (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute...

2014-01-29 08:29:25

- Data expand potential indications both within schizophrenia and to other neuropsychiatric disorders - SEATTLE, Jan. 29, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients...

2014-01-09 16:25:37

OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to twelve weeks of continuous dosing. This is the second study reporting out this...

2014-01-06 16:27:45

Plans to submit end of phase II meeting request to FDA SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by central...

2013-12-09 08:27:18

- Company to Host Conference Call on Monday, December 9, at 10:00 am Eastern Time to Discuss Trial Results - NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("we," "ITI" or "the Company"), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced today positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of its lead drug candidate,...

2013-11-27 08:24:00

NEW YORK, November 27, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), WellPoint Inc. (NYSE: WLP), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Forest Laboratories Inc. (NYSE: FRX), and Envision Healthcare Holdings, Inc. (NYSE: EVHC). Today's readers may access these reports free of charge - including full price...

2013-11-04 12:28:47

BD Simplist(TM) Prefilled Injectable Product Line Expands to Morphine Sulfate Injection, USP at New Manufacturing Facility FRANKLIN LAKES, N.J., Nov. 4, 2013 /PRNewswire/ -- BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that the U.S. Food and Drug Administration (FDA) has approved Morphine Sulfate Injection, USP to be offered in the BD Simplist line of ready-to-administer prefilled injectables...

2013-09-09 16:24:06

Company To Host Conference Call And Webcast Monday, September 9th At 5:00PM ET / 2:00PM PT SAN DIEGO, Sept. 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development for tardive dyskinesia, did not meet the primary endpoint in the Phase IIb Kinect study while the 100mg dose showed a statistical and clinically significant improvement. The pre-specified primary endpoint was the...